1 week Ago By Defense World Staff
Bank of Montreal Can purchased a new position in shares of DiaMedica Therapeutics Inc. ( NASDAQ:DMAC – Free Report ) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 15,560 shares of the company’s stock, valued at approximately $84,000.
Several other institutional investors and hedge funds also recently modified their holdings of DMAC. Geode Capital Management LLC raised its stake in shares of DiaMedica Therapeutics by 29.6% during the third quarter.
Geode Capital Management LLC now owns 306,958 shares of the company’s stock valued at $1,286,000 after purchasing an additional 70,070 shares in the last quarter. Blue Trust Inc. raised its position in shares of DiaMedica Therapeutics by 56.
2% during the 4th quarter. Blue Trust Inc. now owns 69,122 shares of the company’s stock worth $375,000 after buying an additional 24,875 shares in the last quarter.
Y Intercept Hong Kong Ltd acquired a new stake in shares of DiaMedica Therapeutics in the 4th quarter worth approximately $81,000. Meridian Wealth Management LLC bought a new position in shares of DiaMedica Therapeutics in the fourth quarter valued at approximately $148,000. Finally, Raymond James Financial Inc.
acquired a new position in shares of DiaMedica Therapeutics during the fourth quarter valued at approximately $83,000. Institutional investors own 10.12% of the company’s stock.
Analyst Upgrades and Downgrades Separately, HC Wainwright increased their price target on DiaMedica Therapeutics from $7.00 to $10.00 and gave the company a “buy” rating in a research note on Wednesday, March 19th.
DiaMedica Therapeutics Stock Down 3.1 % NASDAQ:DMAC opened at $4.04 on Friday.
DiaMedica Therapeutics Inc. has a 52-week low of $2.14 and a 52-week high of $6.
82. The firm has a market cap of $173.14 million, a P/E ratio of -7.
21 and a beta of 1.50. The business’s 50-day moving average price is $4.
76 and its 200 day moving average price is $5.03. DiaMedica Therapeutics ( NASDAQ:DMAC – Get Free Report ) last announced its quarterly earnings data on Monday, March 17th.
The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.
01). Sell-side analysts expect that DiaMedica Therapeutics Inc. will post -0.
59 EPS for the current year. DiaMedica Therapeutics Profile ( Free Report ) DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.
Read More Five stocks we like better than DiaMedica Therapeutics How to Invest in Small Cap Stocks Markets Think Robinhood Earnings Could Send the Stock Up Find and Profitably Trade Stocks at 52-Week Lows Churchill Downs Stock: Could Tariff Fears Dampen Derby Gains? 3 Natural Gas Stocks That Offer Great Dividend Yields AT&T: Subscriber Growth & Buybacks Signal Bullish Turnaround Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
